Nordea Investment Management AB Reduces Holdings in Charles River Laboratories Intl. Inc (CRL)

Nordea Investment Management AB lowered its stake in Charles River Laboratories Intl. Inc (NYSE:CRL) by 5.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 70,231 shares of the medical research company’s stock after selling 4,410 shares during the period. Nordea Investment Management AB’s holdings in Charles River Laboratories Intl. were worth $7,948,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of CRL. Fort L.P. bought a new position in shares of Charles River Laboratories Intl. in the fourth quarter valued at $27,000. Riverview Trust Co bought a new position in shares of Charles River Laboratories Intl. in the fourth quarter valued at $30,000. Kwmg LLC increased its holdings in shares of Charles River Laboratories Intl. by 32.4% in the fourth quarter. Kwmg LLC now owns 429 shares of the medical research company’s stock valued at $49,000 after buying an additional 105 shares in the last quarter. Captrust Financial Advisors increased its holdings in shares of Charles River Laboratories Intl. by 101.3% in the fourth quarter. Captrust Financial Advisors now owns 612 shares of the medical research company’s stock valued at $69,000 after buying an additional 308 shares in the last quarter. Finally, Csenge Advisory Group bought a new position in shares of Charles River Laboratories Intl. in the third quarter valued at $91,000. 95.15% of the stock is currently owned by institutional investors.

NYSE CRL opened at $145.50 on Tuesday. Charles River Laboratories Intl. Inc has a twelve month low of $101.58 and a twelve month high of $147.85. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.38 and a current ratio of 1.61. The company has a market cap of $7.02 billion, a price-to-earnings ratio of 24.13, a PEG ratio of 1.87 and a beta of 1.04.

Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 13th. The medical research company reported $1.49 earnings per share for the quarter, topping the consensus estimate of $1.39 by $0.10. Charles River Laboratories Intl. had a net margin of 9.99% and a return on equity of 24.09%. The firm had revenue of $605.53 million for the quarter, compared to analysts’ expectations of $589.86 million. During the same period in the previous year, the company posted $1.40 EPS. The company’s quarterly revenue was up 26.5% compared to the same quarter last year. As a group, equities analysts expect that Charles River Laboratories Intl. Inc will post 6.48 earnings per share for the current year.

In other news, EVP Joseph W. Laplume sold 5,522 shares of the business’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $137.61, for a total transaction of $759,882.42. Following the transaction, the executive vice president now directly owns 16,325 shares in the company, valued at approximately $2,246,483.25. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Chairman James C. Foster sold 25,000 shares of the business’s stock in a transaction on Tuesday, January 8th. The shares were sold at an average price of $115.00, for a total transaction of $2,875,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 57,428 shares of company stock worth $7,472,693. 2.10% of the stock is currently owned by corporate insiders.

Several research analysts have issued reports on CRL shares. Morgan Stanley upped their price target on Charles River Laboratories Intl. from $112.00 to $136.00 and gave the company an “equal weight” rating in a report on Monday, December 3rd. Raymond James reaffirmed a “buy” rating and issued a $150.00 price target on shares of Charles River Laboratories Intl. in a report on Tuesday, December 4th. Deutsche Bank began coverage on Charles River Laboratories Intl. in a report on Friday, December 14th. They issued a “buy” rating on the stock. ValuEngine cut shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Friday, January 4th. Finally, Zacks Investment Research cut shares of Charles River Laboratories Intl. from a “hold” rating to a “sell” rating in a research report on Friday, February 8th. Seven investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $142.43.

ILLEGAL ACTIVITY WARNING: “Nordea Investment Management AB Reduces Holdings in Charles River Laboratories Intl. Inc (CRL)” was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://sportsperspectives.com/2019/04/02/nordea-investment-management-ab-reduces-holdings-in-charles-river-laboratories-intl-inc-crl.html.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Article: Why is the price-sales ratio important?

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.